Hong-Yu Li
Title | Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Pharmaceutical Science, College of Pharmacy |
---|
Division | Pharmaceutical Science |
---|
Address | 200 South Cedar Mail Slot # 622 Little Rock AR 72202
|
---|
Phone | 501-296-1154 |
---|
vCard | Download vCard |
---|
|
|
|
Research R01CA249282 (SHAH, NEIL P)Dec 15, 2020 - Nov 30, 2025 NIH Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance Role: Co-Principal Investigator |
| R01CA194094 (LI, HONG-YU)Sep 1, 2016 - Jul 31, 2019 NIH/Nat. Cancer Institute Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML Role: Principal Investigator |
| 340316 (LI, HONG-YU)Apr 1, 2016 - Jun 30, 2016 NIH/Nat. Cancer Institute - Pass Through: University of Arizona Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML Role: Principal Investigator |
| R01CA197178 (LI, HONG-YU)Sep 30, 2015 - Aug 31, 2021 NIH Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer Role: Principal Investigator |
| R01CA197178 (LI, HONG-YU)Sep 30, 2015 - Aug 31, 2021 NIH Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer Role: Principal Investigator |
| R41CA195826 (LI, HONG YU)Sep 1, 2015 - Dec 31, 2016 NIH Pre-IND Study of Pz-1, a dual pan-RET/VEGFR2 inhibitor for the Treatment of RET-driven Disease Role: Principal Investigator |
| R01CA194094 (LI, HONG-YU)Aug 1, 2015 - Jul 31, 2020 NIH Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML Role: Principal Investigator |
| P20GM109005 (BOERMA, MARJAN)Jun 24, 2015 - May 31, 2025 NIH Center for Studies of Host Response to Cancer Therapy Role: Co-Investigator |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Lei J, Song GT, He LJ, Luo YF, Tang DY, Lin HK, Frett B, Li HY, Chen ZZ, Xu ZG. Correction: One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chem Commun (Camb). 2020 Feb 18; 56(14):2210. PMID: 32031562.
-
Lei J, Song GT, He LJ, Luo YF, Tang DY, Lin HK, Frett B, Li HY, Chen ZZ, Xu ZG. One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chem Commun (Camb). 2020 Feb 18; 56(14):2194-2197. PMID: 31971170.
-
Gunaganti N, Kharbanda A, Lakkaniga NR, Zhang L, Cooper R, Li HY, Frett B. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chem Commun (Camb). 2018 Nov 15; 54(92):12954-12957. PMID: 30375586.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2018 | 1 | 2020 | 2 |
To return to the timeline, click here.
|
Li's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|